Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sanofi
ClinicalTrials.gov Identifier:
NCT00952276
First received: August 3, 2009
Last updated: August 26, 2011
Last verified: August 2011

August 3, 2009
August 26, 2011
October 2009
December 2010   (final data collection date for primary outcome measure)
  • Number of Participants With Detectable Antibodies Before and Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age 18 to 64 Years [ Time Frame: Day 0 and Day 21 post-vaccination ] [ Designated as safety issue: No ]
    Antibodies to vaccine were measured using the Hemagglutinin Inhibition (HAI) assay. Detectable anti HA antibody titer was defined as titers ≥ 10 (1/dilution) on Day 0 and Day 21 post-vaccination.
  • Number of Participants With Seroprotection Before and Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age 18 to 64 Years [ Time Frame: Day 0 and Day 21 post-vaccination ] [ Designated as safety issue: No ]
    Antibodies to vaccine were measured using the Hemagglutinin Inhibition (HAI) assay. Seroprotection was defined as a titer ≥ 40 (1/dil).
  • Geometric Mean Titers (GMTs) of A/H1N1 Antibodies Before and Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age 18 to 64 Years [ Time Frame: Day 0 and Day 21 post-vaccination ] [ Designated as safety issue: No ]
    Antibodies to vaccine were measured using the Hemagglutinin Inhibition (HAI) assay.
  • Number of Participants With Detectable Antibodies Before and Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age ≥ 65 Years [ Time Frame: Day 0 and Day 21 post-vaccination ] [ Designated as safety issue: No ]
    Antibodies to vaccine were measured using the Hemagglutinin Inhibition (HAI) assay. Detectable anti-HA antibody titer was defined as titers ≥ 10 (1/dil).
  • Number of Participants With Seroprotection Before and Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age ≥ 65 Years [ Time Frame: Day 0 and Day 21 post-vaccination ] [ Designated as safety issue: No ]
    Antibodies to vaccine were measured using the Hemagglutinin Inhibition (HAI) assay. Seroprotection was defined as a titer ≥ 40 (1/dil).
  • Geometric Mean Titers (GMTs) of A/H1N1 Antibodies Before and Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age ≥ 65 Years [ Time Frame: Day 0 and Day 21 post-vaccination ] [ Designated as safety issue: No ]
    Antibodies to vaccine were measured using the Hemagglutinin Inhibition (HAI) assay.
  • Number of Participants Reporting a Solicited Injection Site or Systemic Reaction Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age 18 to 64 Years [ Time Frame: Day 0 up to Day 7 post-vaccination ] [ Designated as safety issue: No ]
    Solicited Injections Site Reactions: Pain, Erythema, Swelling, Induration, and Ecchymosis. Solicited Systemic Reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Shivering
  • Number of Participants Reporting a Solicited Injection Site or Systemic Reaction Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age ≥ 65 Years [ Time Frame: Day 0 up to Day 7 post-vaccination ] [ Designated as safety issue: No ]
    Solicited Injections Site Reactions: Pain, Erythema, Swelling, Induration, and Ecchymosis. Solicited Systemic Reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Shivering.
  • To provide information concerning the safety after primary administration of influenza A/H1N1 vaccine. [ Time Frame: 0-7 days post-vaccination and entire study duration ] [ Designated as safety issue: Yes ]
  • To provide information concerning the immunogenicity of influenza A/H1N1 vaccine after primary vaccination. [ Time Frame: 21 days post-vaccination ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00952276 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly
Immunogenicity and Safety of Multiple Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adult and Elderly Subjects

The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine in adults and the elderly.

Primary Objectives:

  • To describe the immunogenicity of the candidate vaccines after a single injection.
  • To describe the safety of the candidate vaccines after a single injection.

Participants will receive a single injection of their randomized vaccine on Day 0.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
  • Influenza
  • Swine-origin A/H1N1 Influenza
  • Biological: Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant
    0.5 mL, Intramuscular on Day 0
  • Biological: Monovalent Subvirion A/H1N1 influenza vaccine
    0.5 mL, Intramuscular on Day 0
  • Biological: Normal saline solution
    0.5 mL, Intramuscular on Day 0
    Other Name: Normal saline solution
  • Experimental: A/H1N1 Vaccine Group 1
    Participants will receive A/H1N1 vaccine formulation 1 (with adjuvant)
    Intervention: Biological: Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant
  • Experimental: A/H1N1 Vaccine Group 2
    Participants will receive A/H1N1 vaccine formulation 2 (with adjuvant)
    Intervention: Biological: Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant
  • Active Comparator: A/H1N1 Vaccine Group 3
    Participants will receive A/H1N1 vaccine formulation 3
    Intervention: Biological: Monovalent Subvirion A/H1N1 influenza vaccine
  • Active Comparator: A/H1N1 Vaccine Group 4
    Participants will receive A/H1N1 vaccine formulation 4
    Intervention: Biological: Monovalent Subvirion A/H1N1 influenza vaccine
  • Placebo Comparator: Placebo Group 5
    Participants will receive a placebo vaccine
    Intervention: Biological: Normal saline solution
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
548
March 2011
December 2010   (final data collection date for primary outcome measure)

Inclusion Criteria :

  • Healthy adults aged 18 years or older on the day of inclusion
  • Informed consent has been signed and dated
  • Able to attend all scheduled visits and comply with all trial procedures
  • For a woman of child-bearing potential, use of an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination, until at least 4 weeks after last vaccination.

Exclusion Criteria :

  • Known pregnancy or positive urine pregnancy test
  • Currently breastfeeding a child
  • Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination
  • Planned participation in another clinical trial during the present trial period
  • Receipt of any vaccine in the 4 weeks preceding the trial vaccination, except for the inactivated seasonal influenza vaccine, within two weeks preceding trial vaccination
  • Planned receipt of any vaccine prior to the Day 42 blood sample
  • Receipt of blood or blood-derived products in the past 3 months which might interfere with the assessment of immune response
  • Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  • Self-reported seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B antigen, or Hepatitis C
  • Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances
  • Self reported thrombocytopenia contraindicating intramuscular (IM) vaccination
  • Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion contraindicating IM vaccination
  • Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
  • Current alcohol abuse or drug addiction that may interfere with the subject's ability to comply with trial procedures
  • Chronic illness that in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion
  • Employees of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members of the employees or the Investigator
  • Previous participation in a swine-origin A/H1N1 pandemic flu trial except if performed in 1976
  • Any confirmed case of influenza (including swine-origin A/H1N1 Influenza) since March 2009
  • Febrile illness (temperature ≥ 100.4°F [≥ 38.0°C ]) or moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination
  • Personal or family history of Guillain-Barré syndrome
  • Active neoplastic disease or a history of any hematologic malignancy
  • Known seizure/epilepsy history and/or taking anti-seizure medication
  • Receipt of psychiatric drugs. Subjects receiving a single antidepressant drug and stable for at least 3 months prior to enrollment, without decompensating symptoms will be allowed to enroll in the study
  • Any Grade 1, 2, or 3 liver function values (Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), and Alkaline phosphatase) observed in blood sample taken at Screening
  • Any Grade 2 or Grade 3 laboratory abnormalities in blood sample taken at Screening
  • Receipt of any monovalent 2009 pandemic H1N1 vaccine.
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00952276
FUF16, UTN: U1111-1111-4882
No
Sanofi
Sanofi
Not Provided
Study Director: Medical Monitor Sanofi Pasteur Inc.
Sanofi
August 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP